Articles · HRT
HRT After Surgical Menopause
Removing the ovaries before natural menopause flips the usual risk-and-benefit balance for HRT.
Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.
Surgical menopause happens when both ovaries are removed (bilateral oophorectomy), most often as part of a hysterectomy, as a risk-reducing procedure in women with BRCA mutations, or as treatment for endometriosis. The result is an immediate, complete stop to ovarian estrogen, progesterone, and testosterone production, rather than the gradual years-long decline of natural menopause.
This difference matters clinically. The research on surgical menopause is separate from the research on natural menopause, and the risk-and-benefit balance for HRT is different in ways that are not always explained clearly.
How Surgical Menopause Differs From Natural Menopause
In natural menopause, estrogen declines over several years before the final period. The body has time to adapt. By postmenopause, some adjustment has happened.
In surgical menopause, especially in premenopausal women, the ovaries are removed and estrogen falls to postmenopausal levels within days. There is no transition period. This abrupt withdrawal produces hot flashes that are often more severe than in natural menopause, and long-term health risks that are substantially higher than natural menopause at the same age.[1]
The Long-Term Risk Profile
Research consistently finds higher rates of poor outcomes in women who had their ovaries removed before natural menopause compared with women who had natural menopause at the same age:[1][2]
Heart disease. Early loss of estrogen’s heart protection is more severe with abrupt withdrawal than with gradual decline. Women who had both ovaries removed before 45 have clearly higher rates of heart disease and death from heart disease.
Cognitive decline and dementia. The brain responds strongly to estrogen. Long estrogen loss starting in younger years is linked to higher risk of cognitive impairment and dementia. Several studies find that the earlier the surgery and the longer the estrogen loss, the greater the cognitive risk.[2]
Bone density. Fast bone loss starts right after surgical menopause rather than over several years, and starts from a younger baseline.
Metabolic health. Higher rates of metabolic syndrome, insulin resistance, and obesity have been documented after bilateral oophorectomy, in line with estrogen’s role in metabolism.
Neurological conditions. Some observational data link early bilateral oophorectomy with higher risk of Parkinson’s disease, though the mechanism is not established.
Why HRT Is More Strongly Indicated
For natural menopause, HRT is guided by symptom burden and an individual risk-and-benefit assessment. For surgical menopause in premenopausal women, the framing shifts. Withholding HRT from a surgically menopausal woman under 45 means leaving her with faster heart, bone, and cognitive risk at an age when her peers still have full ovarian function.
The North American Menopause Society recommends that women who have surgical menopause before age 45 should start hormone therapy, and that it should continue at least until the average age of natural menopause (about 51) if well tolerated.[3] The purpose is not comfort. It is reducing health risk.
NICE guidance and the British Menopause Society reach the same conclusion: in women who have both ovaries removed before natural menopause, the risk of withholding HRT exceeds the risk of using it.
What HRT for Surgical Menopause Looks Like
Because the ovaries produced not only estrogen and progesterone but also testosterone, surgical menopause creates a testosterone shortfall alongside the estrogen shortfall. This differs from natural menopause, where the adrenal glands keep producing a share of androgens after ovarian function stops.
The preferred form is transdermal estradiol at an adequate dose, combined with micronised progesterone for women who still have a womb. The dose needed to manage symptoms and reduce health risk in surgical menopause is often higher than standard postmenopausal doses, reflecting the more complete estrogen shortfall.[3]
Testosterone therapy is also relevant, particularly for sexual desire and energy. Given the complete loss of ovarian testosterone production, the case is clearer in surgical than in natural menopause. Transdermal testosterone at physiological female doses has evidence for low sexual desire that causes distress.
For Women With BRCA Mutations
Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1 and BRCA2 mutation carriers to reduce the risk of ovarian and fallopian tube cancer. The timing is driven by cancer risk, not hormonal preference.
For BRCA1 carriers, RRSO is usually recommended between ages 35 and 40. The resulting decades of estrogen loss carry substantial long-term health risk. Research in BRCA mutation carriers who have RRSO finds that HRT does not raise breast cancer risk in this group (removing both ovaries dramatically reduces it), and that HRT restores protection against many of the health risks the surgery introduces.[4]
Women who have had RRSO for BRCA should discuss HRT with both their gynaecologist and their oncologist. The evidence supports its use until at least the age of natural menopause in most BRCA mutation carriers who have not had breast cancer.
References
[1] Parker, W. H., Feskanich, D., Broder, M. S., et al. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstetrics and Gynecology, 121(4), 709-716. See also: Surgical menopause risks overview. https://pmc.ncbi.nlm.nih.gov/articles/PMC7614764/
[2] Rocca, W. A., Bower, J. H., Maraganore, D. M., et al. (2007). Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology, 69(11), 1074-1083. See also: Maintaining cognitive function in surgically menopausal women. https://pmc.ncbi.nlm.nih.gov/articles/PMC8118141/
[3] The Menopause Society (NAMS). Position statement on hormone therapy in women with premature ovarian insufficiency and surgical menopause. See also: Long-term non-cancer risks following RRSO and the role of HRT. https://pmc.ncbi.nlm.nih.gov/articles/PMC9913268/
[4] Marchetti, C., De Felice, F., Boccia, S., et al. (2018). Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Critical Reviews in Oncology/Hematology, 132, 111-115. https://doi.org/10.1016/j.critrevonc.2018.09.018
Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.